Boehringer Ingelheim International Gmbh

Aerie Pharmaceuticals, Inc.

Sabine K Schlyer

Anthony S Prokopowicz

John David Ginn

Frank Wu

Michael Robert Turner

Todd Bosanac

Robert Sibley

Daniel Richard Marshall

Weimin Liu

Roger John Snow

Thomas Martin Kirrane, Jr

Erick Richard Roush Young

Ronald John Sorcek

Alexander Heim-Riether

Fariba Soleymanzadeh

Jennifer A Kowalski

Di Wu

Erick Richard Young

Cheng-Kon Shih

Eugene Richard Hickey

Dieter Wiedenmayer

Angela Kay Berry

Zhonghua Zhang

Zhaoming Xiong

Yunlong Zhang

Donghong Amy Gao

Lana Louise Smith Keenan

Bernd Wellenzohn

Brian Nicholas Cook

Qiang Zhang

Xiang Li

Maolin Yu

Shuang Liang

Steven John Taylor

John A Westbrook

Tamara Denise Hopkins

Lana Louise Smith-Keenan

Neil Alexander Farrow

Thomas Martin Kirrane

Donghong A Gao

Anthony S Iii Prokopowicz

Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.

Rho kinase inhibitors

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R-Rand n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Soluble guanylate cyclase activators

Isoquinolinone Rho kinase inhibitors

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Rand Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Disclosed are compounds and compositions of the formula (I) as described herein which are inhibitors of MMP-13. Also disclosed are methods of using and making compounds of the formula (I). 

Heteroaryl diamide compounds useful as MMP-13 inhibitors

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Rto R, A, B, D and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

CXCR3 receptor antagonists

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Rto R, A, B, X, Y and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Disclosed are compounds and compositions of the formula I as described herein which are inhibitors of MMP-13. Also disclosed are methods of using and making compounds of the formula I. 

Fused heteroaryl diamide compounds useful as MMP-13 inhibitors

Growing community of inventors

New Milford, CT, United States of America

Sabine K Schlyer